All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma

ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, AU, about the efficacy of the novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL).

Michael Dickinson describes CD20-TCB as a CD20 CD3 bispecific antibody, which was tested in non-Hodgkin lymphoma, targeting CD20. Despite toxicities being observed in patients, it is still early days, with promising results for patients with a very aggressive refractory condition.

ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL

Share: